Logotipo do repositório
 

Publicação:
Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis

dc.contributor.authorFernandes, Joao Paulo-dos Santos
dc.contributor.authorPavan, Fernando Rogério [UNESP]
dc.contributor.authorLeite, Clarice Queico Fujimura [UNESP]
dc.contributor.authorAndres Felli, Veni Maria
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-03-18T15:53:38Z
dc.date.available2015-03-18T15:53:38Z
dc.date.issued2014-09-01
dc.description.abstractTuberculosis (TB) is a disease caused mainly by infection of Mycobacterium tuberculosis affecting more than ten million people around the world. Despite TB can be treated, the rise of MDR-TB and XDR-TB cases put the disease in a worrying status. As pyrazinamide-resistant strains exhibit low or none pyrazinamidase activity, it is proposed that the active form of pyrazinamide (PZA) is pyrazinoic acid (POA), although this acid has poor penetration in mycobacteria. In this work, we present a convenient one-pot synthesis of 2-chloroethyl pyrazinoate, and its activity in M. tuberculosis H(37)Rv (ATCC27294) in MIC assay using the MABA technique. The obtained MIC of the compound was 3.96 g/mL, and discussion about the activity profile of some previously evaluated pyrazinoates is also performed. (C) 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.en
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Inst Environm Chem & Pharmaceut Sci, Sao Paulo, Brazil
dc.description.affiliationState Univ Sao Paulo UNESP, Fac Pharmaceut Sci, Dept Biol Sci, Sao Paulo, Brazil
dc.description.affiliationUniv Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, BR-05508 Sao Paulo, Brazil
dc.description.affiliationUnespState Univ Sao Paulo UNESP, Fac Pharmaceut Sci, Dept Biol Sci, Sao Paulo, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipPROPE
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.format.extent376-380
dc.identifierhttp://dx.doi.org/10.1016/j.jsps.2013.12.005
dc.identifier.citationSaudi Pharmaceutical Journal. Amsterdam: Elsevier Science Bv, v. 22, n. 4, p. 376-380, 2014.
dc.identifier.doi10.1016/j.jsps.2013.12.005
dc.identifier.fileWOS000341120900013.pdf
dc.identifier.issn1319-0164
dc.identifier.lattes2114570774349859
dc.identifier.urihttp://hdl.handle.net/11449/116638
dc.identifier.wosWOS:000341120900013
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofSaudi Pharmaceutical Journal
dc.relation.ispartofjcr3.110
dc.relation.ispartofsjr0,687
dc.rights.accessRightsAcesso abertopt
dc.sourceWeb of Science
dc.subjectAntimycobacterial agenten
dc.subjectEster synthesisen
dc.subjectProdrugen
dc.subjectPyrazinoic aciden
dc.subjectTuberculostaticen
dc.titleSynthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosisen
dc.typeArtigopt
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.author.lattes2114570774349859
unesp.author.orcid0000-0002-6969-3963[2]
unesp.author.orcid0000-0002-9089-273X[1]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentCiências Biológicas - FCFpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
WOS000341120900013.pdf
Tamanho:
464.75 KB
Formato:
Adobe Portable Document Format